Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 6, 2022
Daily News
July 6, 2022
- Astellas CEO Sees Lower SGA and Trial Costs and Higher Research and Manufacturing Outlays Post-COVID
July 6, 2022
- Mitsubishi Tanabe Recalls Tranquilizer Depas over Contamination
July 6, 2022
- Kitasato Pharma to Be Dissolved at September-End: Meiji
July 6, 2022
- Astellas, Mogrify Ink Regenerative Medicine Collab for Sensorineural Hearing Loss
July 6, 2022
- Astellas Looks to Beat Innovation Malaise through Organizational and HR Rejig
July 6, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…